Introduction
============

Schizophrenia is a serious long-term psychiatric disorder treated primarily with antipsychotic drugs. However, each intervention has side effects and in the case of typical antipsychotics, such as haloperidol and perphenazine, tardive dyskinesia (TD) is one of them. TD is a severe, potentially irreversible movement disorder that is characterized by athetoid movements that affect mainly the mouth, tongue, jaw, and muscles for facial expressions; it may also affect the upper limbs, lower limbs, neck and trunk. These movements may persist even after medication has been withdrawn and can worsen with age ([@B38]). Between 20 and 25% of chronic schizophrenia patients treated with first-generation antipsychotics develop TD ([@B29]; [@B42]). The risk of TD has been associated with older age, female sex, longer duration of antipsychotic treatment, and use of older, typical, first-generation antipsychotics such as haloperidol, perphenazine, and chlorpromazine ([@B30]). Atypical antipsychotics, such as clozapine, olanzapine, and quetiapine, are associated with a lower risk of developing TD ([@B38]). While TD rates have declined with increased use of atypical antipsychotics, TD risk has not been completely eliminated ([@B13]).

The cause of TD remains unclear. The mechanism of TD development has been hypothesized to involve supersensitivity of the nigrostriatal dopaminergic pathway, damage to neurons by free radical overproduction, and dysregulation of the GABAergic system ([@B26]). Familial occurrence of TD also supports a genetic component in TD ([@B44]; [@B45]; [@B31]). As such, a number of findings have emerged from candidate gene studies ([@B48]). For example, the dopamine D2 receptor (*DRD2)* gene has been a primary candidate ([@B46]; [@B9]). More recently, there is growing evidence that the vesicular monoamine transporter 2 (VMAT2/SLC18A2) gene may be associated with TD, including association findings from genetic studies ([@B43]; [@B51]) and promising findings from clinical trials on the VMAT2 inhibitors deutetrabenazine and valbenazine as treatment for TD ([@B3]; [@B14]; [@B15]; [@B21]). However, the associated genetic markers had only moderate effect sizes, suggesting additional genetic factors likely contribute to TD susceptibility. A number of genome-wide association studies (GWASs) of TD have been conducted ([@B1]; [@B18]; [@B41]), leading to a number of novel candidate genes, including the Perlecan-coding gene *HSPG2* (also known as Heparan Sulfate Proteoglycan 2; HGNC ID: 5273; at 1p36.12).

The *HSPG2* rs2445142 G allele was found to be the risk allele for TD in a GWAS on 86 Japanese schizophrenia patients with treatment-resistant TD and 186 without. This allele was also associated with an increase in gene expression in human prefrontal cortical tissues ([@B41]). Administrations of the typical antipsychotic haloperidol in mice increased HSPG2 expression after 4 weeks, but decreased expression after 50 weeks ([@B41]). More importantly, *Hspg2* deficiency led to fewer vacuous chewing movements in a mouse model of TD ([@B41]). The *HSPG2* association was replicated in a refined sample from the CATIE trial, consisting of 179 schizophrenia patients of European ethnicity ([@B19]), as well as a sample of Jewish Israeli schizophrenia patients ([@B19]). Thus, to further validate these findings, we conducted an association study of *HSPG2* rs2445142 with TD and followed up with a meta-analysis.

Materials and Methods {#s1}
=====================

Subjects
--------

For this meta-analysis, we added two datasets to the currently available data from the literature. The first dataset included 217 participants from two samples (Canada, United States) for which the sample characteristics have been described previously ([@B11]; [@B47], [@B50]). Briefly, participants were enrolled from one site in Canada and three sites in the United States: Center for Addiction and Mental Health in Toronto, Toronto, ON, Canada (Dr. G. Remington, *N* = 94); Case Western Reserve University in Cleveland, Cleveland, OH, United States (Dr. H. Y. Meltzer, *N* = 63); Hillside Hospital in Glen Oaks, Glen Oaks, NY, United States (Dr. J. A. Lieberman, *N* = 48); and University of California at Irvine, Irvine, CA, United States (Dr. S. G. Potkin, *N* = 12). Participants had DSM-III-R or DSM-IV diagnoses of schizophrenia or schizoaffective disorder ([@B2]); individuals with type II diabetes, head injury with loss of consciousness, or seizure disorder were excluded from the study. Patients recruited in the United States (HYM, JAL, SGP) had no prior exposure to atypical antipsychotics, while the chronic patients from Canada (GR) may have been on either typical or atypical antipsychotics. Overall, all patients had been exposed to typical antipsychotic medication for at least 1 year before TD assessment. The rate of TD was not significantly different between the United States (38%) and Canadian (43%) samples (*p* = 0.58), and was lower, albeit not significantly, in males (36%) versus females (49%) in the collective sample (*p* = 0.11).

Our second dataset consisted of schizophrenia or schizoaffective disorder patients from a naturalistic pharmacogenetic study \[The Individualized Medicine: Pharmacogenetics Assessment and Clinical Treatment (IMPACT, *N* = 20 TD cases and 41 TD-negative controls at baseline)\] ([@B22]).

The classification of TD was based on the Schooler and Kane criteria, using the Abnormal Involuntary Movement Scale (AIMS) or the modified Hillside Simpson Dyskinesia Scale (HSDS) for the 48 patients recruited from the Hillside Hospital ([@B35]; [@B11]). Thus, presence of TD included at least one moderate rating or at least two mild ratings on the first seven items of the AIMS ([@B35]). Because of previous findings of a higher rate of TD in patients of African ancestry compared to those of European ancestry, we analyzed our self-reported African (*N* = 30, 11 of which were classified as having TD) and European (*N* = 187, of which 76 were positive for TD) subjects separately ([@B23]; [@B38]). AIMS scores were available for 155 European patients and 26 African patients. Our European sample has over 80% power to detect an odds ratio of 2.07 \[α = 0.05, allele frequency = 0.2, additive model; Quanto v1.2.3; ([@B17])\]. This study was carried out in accordance with the recommendations of Tri-Council Policy Statement 2 and Good Clinical Practice. The protocol was approved by the individual institutional research ethics boards. All subjects gave written informed consent in accordance with the Declaration of Helsinki.

Genotyping and Analysis
-----------------------

We genotyped the *HSPG2* rs2445142 single-nucleotide polymorphism by polymerase chain reaction amplification with the TaqMan genotyping assay C\_\_16231131_10 (Thermo Fisher Scientific) following the manufacturer's protocol, followed by genotype determination in the ViiA 7 Real-Time PCR System. Ten percent of the genotypes were repeated for quality assurance, and no mismatches were observed.

Tests for deviation from Hardy--Weinberg Equilibrium were conducted using Haploview ([@B10]). We conducted logistic regression analysis of TD occurrence and linear regression analysis of log-transformed AIMS scores using the entire sample, including age and sex as covariates (SPSS).

We carried out the meta-analysis using the R package 'meta' with the Mantel-Haenszel fixed-effect method. Using search terms "tardive" and "HSPG2" in PubMed, Scopus, and Web of Science, we found 11 studies, of which six were excluded because they represented review articles ([@B26]; [@B27]; [@B24]; [@B48],[@B49]), one was excluded because it was not a gene association study ([@B36]), one was excluded because the article was in Japanese ([@B7]), and one was excluded because the underlying diagnosis was not specified ([@B8]). We were able to obtain allele counts for TD cases and controls for the meta-analysis from two studies ([@B41]; [@B19]). For the [@B19] study, there was also genotype data on rs878949, which is a proxy marker for rs2445142 in a sub-group of the CATIE sample. We included our TD samples (Canada-European, United States-European, Canada/United States-African American, and PGX-European) in the meta-analysis (**Table [1](#T1){ref-type="table"}**).

###### 

Demographic information on the samples included in the meta-analysis.

  Study/sample                      N (TD cases/TD-negative controls)   Ethnicity          Mean age (years)   Males/females
  --------------------------------- ----------------------------------- ------------------ ------------------ ---------------
  [@B41]                            86/186                              Japanese           56.57              164/110
  [@B19] Israeli                    73/91                               Jewish             48.7               89/75
  [@B19] CATIE^∗^                   75/101                              European           41.5               145/31
  [@B51] Canada^∗∗^                 40/52                               European           42.48              59/33
  [@B51] United States^∗∗^          24/31                               European           34.75              39/16
  [@B51] Canada/United States^∗∗^   6/13                                African American   29.74              15/4
  [@B22] IMPACT^∗∗^                 20/41                               European           41.2               46/15

∗

For the CATIE sample, rs878949 genotypes were used as proxies for rs2445142 genotypes.

∗∗

Previously unpublished data on HSPG2 rs2445142.

Results
=======

The genotypes for *HSPG2* rs2445142 did not deviate significantly from Hardy--Weinberg Equilibrium (*p* \> 0.05). Our analysis of *HSPG2* rs2445142 in our samples did not yield significant findings with TD occurrence or severity as measured by AIMS (*p* \> 0.05). In the CAMH European sample, the marker was not associated with log-transformed total AIMS scores (*t* = 0.162, *p* = 0.872) or TD occurrence \[Odds Ratio (adjusted for sex and age) = 1.08, 95% confidence interval: 0.61--1.89; Wald = 0.028; *p* = 0.868\]. Similarly, in the CAMH IMPACT sample, the marker was not associated with log-transformed total AIMS scores (*t* = 1.122, *p* = 0.267) or TD occurrence \[Odds Ratio (adjusted for sex and age) = 1.22, 95% confidence interval: 0.47--3.17; Wald = 0.168; *p* = 0.682\].

We performed a meta-analysis of *HSPG2* rs2445142 in TD occurrence including the [@B41] discovery sample, [@B19] Israeli and selected CATIE samples, and our Canada (European), United States (European), Canada/United States (African American), and IMPACT (European) samples, totaling 324 TD cases and 515 TD-negative controls. The G-allele was significantly associated with TD \[fixed-effects model: OR(G) = 1.51, 95% confidence interval: 1.22--1.86; *p* = 0.0001; Heterogeneity *p* = 0.23\], and no significant heterogeneity was observed among the studies included in the meta-analysis (**Table [2](#T2){ref-type="table"}**). In addition, the test for Funnel plot asymmetry indicated that the meta-analysis did not suffer from significant publication bias (*p* = 0.116). Meta-regression analyses found age to have a significant effect on our findings \[Q(df = 1) = 7.62; *p* = 0.006\], while sex appeared to have a trend effect \[Q(df = 1) = 3.18; *p* = 0.075\]. Results from the sensitivity analysis showed that the [@B41] dataset contributed to most of the association signal as well as heterogeneity (**Table [3](#T3){ref-type="table"}**). Nonetheless, the direction of effect remained the same throughout the sensitivity analysis.

###### 

Results from meta-analysis of HSPG2 rs2445142 with TD occurrence.

  Study                            Odds ratio   95%-Confidence interval   %Weight (fixed)   %Weight (random)
  -------------------------------- ------------ ------------------------- ----------------- ------------------
  [@B41]                           2.249        1.545--3.272              25.5              26.1
  [@B19] Israeli                   1.599        0.981--2.607              18.2              19
  [@B19] CATIE                     1.232        0.791--1.918              25.1              21.5
  [@B51] Canada^∗^                 1.035        0.535--2.003              12.2              12.3
  [@B51] United States^∗^          1.073        0.471--2.446              7.7               8.5
  [@B51] Canada/United States^∗^   0.857        0.218--3.371              3.1               3.4
  [@B22] IMPACT^∗^                 1.189        0.541--2.611              8.1               9.2
  Fixed-effects model^a^           1.507        1.220--1.861              100               
  Random-effects model^b^          1.442        1.111--1.873                                100

a

Fixed-effects model p = 0.0001;

b

random-effects model p = 0.006.

∗

Previously unpublished data on HSPG2 rs2445142.

###### 

Results from sensitivity analysis under fixed-effects model.

  Sample omitted                Odds ratio   95%-Confidence interval   *p*-Value   Tau^2^   I^2^ (%)
  ----------------------------- ------------ ------------------------- ----------- -------- ----------
  [@B41]                        1.2525       0.970--1.618              0.0847      0        0.00
  [@B19] Israeli                1.4863       1.176--1.878              0.0009      0.0596   37.90
  [@B19] CATIE                  1.5987       1.257--2.033              0.0001      0.0428   29.40
  [@B51] Canada                 1.5726       1.259--1.965              \<0.0001    0.0299   25.70
  [@B51] United States          1.5431       1.241--1.920              \<0.0001    0.0396   32.60
  [@B51] Canada/United States   1.5278       1.234--1.892              0.0001      0.0376   32.90
  [@B22] IMPACT                 1.5349       1.233--1.911              0.0001      0.0453   35.40

Discussion
==========

We have conducted an association study and meta-analysis of the *HSPG2* rs2445142 marker in TD occurrence. The finding of the G allele being associated with risk for TD supports a role of this marker in TD, though similar to the meta-analysis of *DRD2* rs1800497 in TD, the effect size of 1.507 was not substantial, thus supporting the notion that TD risk reflects multiple genetic factors.

There are a number of points to consider for the present study. First, the persistence of TD case and TD control status was only assessed in two of the seven included samples ([@B41]; [@B19]). Longer term longitudinal observations that include examinations of the fluctuation patterns of TD may help strengthen the genetic findings. In addition, results from the sensitivity analysis indicated that most of the signal may be coming from the discovery sample ([@B41]), and the observed effect may diminish with subsequent studies. Thus, international efforts are need to provide additional independent replications in large samples, especially for genetic associations with small effect sizes. Moreover, the minor allele frequencies differed across ethnicities, and findings may also be more relevant for East Asian samples in which the original findings were found. Replication studies on patients of various ethnicities may provide insight into whether the genetic association is stronger in East Asians than other populations.

Mutations in the *HSPG2* gene have been observed in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia), which is an autosomal recessive disorder characterized by bone dysplasia and myotonia ([@B32]; [@B4]; [@B39]). This association was supported in mice with reduced expression of perlecan ([@B6]; [@B34]; [@B40]). In addition, somatic mutations in *HSPG2* have also been associated with aging of skeletal muscles ([@B16]), which are coated by a perlecan-containing basement membrane. Perlecan has been found at the neuromuscular junction and is required for acetylcholinesterase clustering at the synapse ([@B5]; [@B20]; [@B37]). Because acetylcholinesterase terminates synaptic transmission through the breakdown of acetylcholine, mutations in *HSPG2* may prevent the degradation of acetylcholine, leading to muscle over-excitation ([@B12]). Perlecan is also a part of the basement membrane extracellular matrix that makes up part of the blood--brain barrier ([@B33]; [@B28]). Its C-terminal domain V fragment may play a neuroprotective role following ischemic stroke ([@B25]). Further work investigating the role of perlecan in neuromuscular junctions and neuroprotection as well as exploring the perlecan-related biological pathways through GWAS approaches will improve our understanding of the potential role this protein plays in TD.
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